• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将罕见病管理纳入印度公共卫生计划:探索国家卫生使命的潜力。

Integrating rare disease management in public health programs in India: exploring the potential of National Health Mission.

机构信息

DST Center for Policy Research, Indian Institute of Science, Bengaluru, India.

出版信息

Orphanet J Rare Dis. 2022 Feb 10;17(1):43. doi: 10.1186/s13023-022-02194-z.

DOI:10.1186/s13023-022-02194-z
PMID:35144652
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8832777/
Abstract

Rare diseases (RD) are conditions that affect a small number of people and hence do not get the focus on government health priorities in a resource-constrained setting such as India. Therefore, it is essential to focus on strengthening and utilizing the existing public health framework for the optimal usage of healthcare resources. In this regard, National Health Mission (NHM) is one of the crucial programs initiated by the government of India to address the health needs of the under-served. As Phase 1 of the NHM moves towards completion, we explored the Reproductive, Maternal, Newborn, Child, and Adolescent Health (RMNCH + A) program under NHM to assess their potential and limitations to aid RD care. We found that some of the disease-prevention initiatives of NHM address certain RDs and can easily be expanded to manage many such preventable RDs. In addition, NHM programs can provide a unique epidemiological data repository to strengthen the National Rare Disease Registry. These programs can also play important role in providing a continuum of care for many RDs that need lifelong management. However, existing programs have a limited scope to provide specialized RD-related treatments, which is better served in a more focused system. Thus, considering RDs in the design of the existing programs may help RD management better through prevention, data collection, and providing a continuum of care.

摘要

罕见病是指在资源有限的情况下,影响少数人群的疾病,因此在政府卫生重点事项中往往得不到关注,比如在印度。因此,必须专注于加强和利用现有的公共卫生框架,以优化医疗资源的利用。在这方面,国家健康使命(NHM)是印度政府启动的关键项目之一,旨在满足服务不足人群的健康需求。随着 NHM 的第一阶段接近完成,我们探索了 NHM 下的生殖、孕产妇、新生儿、儿童和青少年健康(RMNCH+A)计划,以评估其在援助罕见病护理方面的潜力和局限性。我们发现,NHM 的一些疾病预防计划针对某些罕见病,并且可以轻松扩展以管理许多此类可预防的罕见病。此外,NHM 计划可以提供独特的流行病学数据存储库,以加强国家罕见病登记处。这些计划还可以在为需要终身管理的许多罕见病提供连续护理方面发挥重要作用。然而,现有计划在提供专门的罕见病相关治疗方面的范围有限,而这在更集中的系统中可以得到更好的服务。因此,在现有计划的设计中考虑罕见病,可以通过预防、数据收集和提供连续护理,更好地管理罕见病。

相似文献

1
Integrating rare disease management in public health programs in India: exploring the potential of National Health Mission.将罕见病管理纳入印度公共卫生计划:探索国家卫生使命的潜力。
Orphanet J Rare Dis. 2022 Feb 10;17(1):43. doi: 10.1186/s13023-022-02194-z.
2
Expansion of India's national child healthcare programme, Rashtriya Bal Swasthya Karyakram (RBSK), for rare disease management : a health policy perspective.印度国家儿童医疗保健计划(Rashtriya Bal Swasthya Karyakram,RBSK)在罕见病管理方面的扩展:从卫生政策角度看。
Orphanet J Rare Dis. 2023 Jun 12;18(1):145. doi: 10.1186/s13023-023-02761-y.
3
Newborn healthcare in urban India.印度城市的新生儿医疗保健
J Perinatol. 2016 Dec;36(s3):S24-S31. doi: 10.1038/jp.2016.187.
4
The role of patient organizations in the rare disease ecosystem in India: an interview based study.患者组织在印度罕见病生态系统中的作用:基于访谈的研究。
Orphanet J Rare Dis. 2019 May 29;14(1):117. doi: 10.1186/s13023-019-1093-6.
5
Tackling rare diseases at European level: why do we need a harmonized framework?在欧洲层面应对罕见病:我们为何需要一个统一的框架?
Folia Med (Plovdiv). 2007;49(1-2):59-67.
6
Adolescent health programming in India: a rapid review.印度青少年健康计划:快速审查。
Reprod Health. 2020 Jun 3;17(1):87. doi: 10.1186/s12978-020-00929-4.
7
Prioritization of research engaged with rare disease stakeholders: a systematic review and thematic analysis.优先考虑与罕见病利益相关者合作的研究:系统评价和主题分析。
Orphanet J Rare Dis. 2023 Nov 23;18(1):363. doi: 10.1186/s13023-023-02892-2.
8
India's RMNCH+A Strategy: approach, learnings and limitations.印度的妇幼保健及儿童和青少年卫生与营养战略:方法、经验教训与局限性
BMJ Glob Health. 2019 May 4;4(3):e001162. doi: 10.1136/bmjgh-2018-001162. eCollection 2019.
9
General public's understanding of rare diseases and their opinions on medical resource allocation in Japan: a cross-sectional study.公众对罕见病的认知及对日本医疗资源配置的意见:一项横断面研究。
Orphanet J Rare Dis. 2023 Jun 8;18(1):143. doi: 10.1186/s13023-023-02762-x.
10
Rare Diseases in Europe: from a Wide to a Local Perspective.欧洲的罕见病:从宏观到局部视角
Isr Med Assoc J. 2016 Jun;18(6):359-63.

引用本文的文献

1
Systemic barriers to rare disease management in conflict zones: insights from a refugee with sturge-weber syndrome in Sudan.冲突地区罕见病管理的系统性障碍:来自苏丹一名患有斯特奇-韦伯综合征难民的见解。
J Health Popul Nutr. 2025 Apr 2;44(1):103. doi: 10.1186/s41043-025-00845-y.
2
The involvement of non-governmental organisations in achieving health system goals based on the WHO six building blocks: A scoping review on global evidence.非政府组织基于世界卫生组织的六大要素在实现卫生系统目标方面的参与:一项关于全球证据的范围审查
PLoS One. 2025 Jan 30;20(1):e0315592. doi: 10.1371/journal.pone.0315592. eCollection 2025.
3
Systematic Literature Review of Access Pathways to Drugs for Patients with Rare Diseases.罕见病患者药物获取途径的系统文献综述
Appl Health Econ Health Policy. 2025 Mar;23(2):209-229. doi: 10.1007/s40258-024-00939-4. Epub 2024 Dec 28.
4
Navigating health policies and programs in India: exploring opportunities to improve rare disease management and orphan drug research.在印度,探索卫生政策和项目:改善罕见病管理和孤儿药研究的机会。
Orphanet J Rare Dis. 2024 Nov 29;19(1):446. doi: 10.1186/s13023-024-03377-6.
5
Expansion of India's national child healthcare programme, Rashtriya Bal Swasthya Karyakram (RBSK), for rare disease management : a health policy perspective.印度国家儿童医疗保健计划(Rashtriya Bal Swasthya Karyakram,RBSK)在罕见病管理方面的扩展:从卫生政策角度看。
Orphanet J Rare Dis. 2023 Jun 12;18(1):145. doi: 10.1186/s13023-023-02761-y.
6
Balancing patient need with public policy in rare diseases - A legal perspective.从法律角度平衡罕见病患者需求与公共政策
Indian J Ophthalmol. 2022 Jul;70(7):2584. doi: 10.4103/ijo.IJO_905_22.

本文引用的文献

1
Universal Implementation of Newborn Screening in India.印度新生儿筛查的全面实施。
Int J Neonatal Screen. 2020 Mar 25;6(2):24. doi: 10.3390/ijns6020024. eCollection 2020 Jun.
2
The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study.印度孤儿药组织的工作、目标、挑战、成就和建议:基于访谈的研究。
Orphanet J Rare Dis. 2019 Nov 4;14(1):241. doi: 10.1186/s13023-019-1224-0.
3
Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database.估算罕见病的累计点患病率:对孤儿药数据库的分析。
Eur J Hum Genet. 2020 Feb;28(2):165-173. doi: 10.1038/s41431-019-0508-0. Epub 2019 Sep 16.
4
The role of patient organizations in the rare disease ecosystem in India: an interview based study.患者组织在印度罕见病生态系统中的作用:基于访谈的研究。
Orphanet J Rare Dis. 2019 May 29;14(1):117. doi: 10.1186/s13023-019-1093-6.
5
The burden of rare diseases.罕见病的负担。
Am J Med Genet A. 2019 Jun;179(6):885-892. doi: 10.1002/ajmg.a.61124. Epub 2019 Mar 18.
6
Newborn Screening for Congenital Hypothyroidism and Congenital Adrenal Hyperplasia.新生儿先天性甲状腺功能减退症和先天性肾上腺皮质增生症筛查。
Indian J Pediatr. 2018 Nov;85(11):935-940. doi: 10.1007/s12098-018-2645-9. Epub 2018 Mar 17.
7
High Risk Stratified Neonatal Screening.高危分层新生儿筛查。
Indian J Pediatr. 2018 Dec;85(12):1050-1054. doi: 10.1007/s12098-017-2545-4. Epub 2018 Mar 15.
8
Prevalence of Congenital Anomalies in an Indian Maternal Cohort: Healthcare, Prevention, and Surveillance Implications.印度孕产妇队列中先天性异常的患病率:对医疗保健、预防及监测的启示
PLoS One. 2016 Nov 10;11(11):e0166408. doi: 10.1371/journal.pone.0166408. eCollection 2016.
9
Inborn errors of metabolism in a tertiary care hospital of eastern India.印度东部一家三级医疗医院的先天性代谢缺陷
Indian Pediatr. 2013 Dec;50(12):1155-6. doi: 10.1007/s13312-013-0303-x.
10
Birth defects in India: Hidden truth, need for urgent attention.印度的出生缺陷:隐藏的真相,亟待关注。
Indian J Hum Genet. 2013 Apr;19(2):125-9. doi: 10.4103/0971-6866.116101.